Clinical Trials Browser

Phase 3 × olaparib × Gynecologic × Clear all

NCT04729387 2026-06-04

Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected

Phase 3 Terminated

358 enrolled 19 charts

Ovarian Neoplasms

NCT02446600 2026-06-03

Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 3 Active not recruiting

579 enrolled 17 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06915025 2026-06-02

OVATION-3

Phase 3 Recruiting

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04269200 2026-06-01

DUO-E

Phase 3 Active not recruiting

805 enrolled 18 charts 1 FDA

Endometrial Neoplasms

NCT03740165 2026-05-04

KEYLYNK-001

Phase 3 Completed

1,367 enrolled 29 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

NCT04421963 2026-04-16

ROSY-O

Phase 3 Active not recruiting

BreastGynecologic

Breast Neoplasms, Neoplasms, Ovarian Neoplasms

NCT06580314 2026-03-24

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

Phase 3 Recruiting

Ovarian Neoplasms

NCT04884360 2026-03-02

MONO-OLA1

Phase 3 Active not recruiting

Ovarian Neoplasms

NCT06712472 2026-01-20

RAINBO-RED

Phase 3 Recruiting

Endometrial Neoplasms

NCT01844986 2025-12-10

SOLO-1

Phase 3 Active not recruiting

450 enrolled 18 charts 1 FDA

Pathologic Complete Response, Ovarian Neoplasms

NCT01874353 2025-08-03

Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy

Phase 3 Active not recruiting

327 enrolled 21 charts 1 FDA

Ovarian Neoplasms

NCT03534453 2025-07-10

L-MOCA

Phase 3 Completed

Ovarian Neoplasms

NCT03737643 2025-01-29

DUO-O

Phase 3 Active not recruiting

1,407 enrolled 1 FDA

Ovarian Neoplasms

NCT03402841 2024-08-21

OPINION

Phase 3 Completed

279 enrolled 17 charts

Ovarian Neoplasms

NCT05255471 2023-03-24

MITO 35B

Phase 3 Recruiting

Ovarian Neoplasms

NCT03106987 2022-10-07

OReO

Phase 3 Completed

220 enrolled 21 charts

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT03278717 2022-09-27

ICON9

Phase 3 Unknown

Ovarian Neoplasms

NCT02477644 2022-08-02

PAOLA-1

Phase 3 Completed

Ovarian Neoplasms

NCT02282020 2022-07-26

SOLO3

Phase 3 Completed

266 enrolled 31 charts

Ovarian Neoplasms

NCT02392676 2016-05-02

Olaparib Maintenance Treatment Versus Placebo in Patients With PSR Ovarian Cancer Who Are in CR or PR to Platinum-based Chemotherapy and Whose Tumours Carry sBRCAm or HRR-associated Genes Mutations

Phase 3 Withdrawn

Ovarian Neoplasms